Teva and Baxter to appeal $500 million US hepatitis propofol vial reuse award
This article was originally published in Scrip
Executive Summary
A unit of Teva Pharmaceutical Industries and Baxter Healthcare plan to appeal a combined $500 million punitive damages award of a Las Vegas jury, which found that vials of the anaesthetic propofol were not packaged with adequate warnings about improper use, specifically the dangers of reusing single-use vials among multiple patients. The case was the first to go to trial after an outbreak of hepatitis C several years ago in Southern Nevada, and hundreds of other lawsuits remain.